Thursday, July 9, 2026

pharma · Osteopenia · Heat Stress · PTPI

Petros Pharmaceuticals

Petros Pharmaceuticals is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker PTPI. Primary therapeutic focus areas include Osteopenia, Heat Stress, Risk of Heat Stress. NovaPharmaNews li

New York, USA HQ
3 Employees
Public company Type
PTPI · NYSE Ticker
Company details
Status
Public
HQ
New York, USA
Employees
3
Programs
3
Drugs
3
Patents
0

Quick answer

Petros Pharmaceuticals is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker PTPI. Primary therapeutic focus areas include Osteopenia, Heat Stress, Risk of Heat Stress. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

Company snapshot

At Petros, we are bringing new approaches to the most challenging conditions in men's health. We seek to understand the various health phases throughout a man’s journey. We collaborate with researchers, scientists, medical thought leaders and payers to ensure our therapies aid in restoring men’s body function to vitality. Please see the full Prescribing Information and Patient Information: https:/

  • 3 active pipeline program(s) linked via ClinicalTrials.gov.
  • 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Petros Pharmaceuticals. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Petros Pharmaceuticals.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 3 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Petros Pharmaceuticals.

  1. Clinical update

    Neutral environment with radiation — Unknown

  2. Clinical update

    Thermal stress and performance without a pre-cooling protocol — Unknown

  3. Clinical update

    Colostrum supplementation for bone loss — Unknown

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Petros Pharmaceuticals?

    Petros Pharmaceuticals is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker PTPI. Primary therapeutic focus areas include Osteopenia, Heat Stress, Risk of Heat Stress. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent r

  • Is Petros Pharmaceuticals publicly traded?

    Yes. Petros Pharmaceuticals is listed with ticker PTPI on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Petros Pharmaceuticals develop or market?

    We link 3 drug profile(s) where Petros Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/petros-pharmaceuticals#company-drugs.

  • What are the latest developments for Petros Pharmaceuticals?

    In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Petros Pharmaceuticals focus on?

    Petros Pharmaceuticals focuses on Osteopenia, Heat Stress, Risk of Heat Stress based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
6